BACKGROUND Genome wide association study (GWAS)-linked variant (Park16 rs6679073) modulates the risk of Parkinson's disease (PD). We postulate that there may be differences in clinical characteristics between Park16 rs6679073 carriers… Click to show full abstract
BACKGROUND Genome wide association study (GWAS)-linked variant (Park16 rs6679073) modulates the risk of Parkinson's disease (PD). We postulate that there may be differences in clinical characteristics between Park16 rs6679073 carriers and non-carriers. AIM In a prospective study, we investigate the clinical characteristics between Park16 rs6679073 A allele carriers and non-carriers over 4 years. METHODS AND RESULTS A total of 204 PD patients, comprising 158 Park16 rs6679073 A allele carriers and 46 non carriers were recruited. All patients underwent motor, non-motor symptoms and cognitive assessments yearly over 4 years. Park16 rs6679073 carriers were less likely to have mild cognitive impairment (MCI) compared to non-carriers at both baseline (48.1% vs 67.4%, p=0.027) and 4-year follow-up (29.3% vs 58.6%, p=0.007). CONCLUSION PD Park16 rs6679073 carriers had significantly lower frequency of MCI in a 4-year follow-up study, suggesting that the variant may have potential neuroprotective effect on cognitive functions.
               
Click one of the above tabs to view related content.